BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37889309)

  • 21. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma.
    Gao W; He X; Huangfu Q; Xie Y; Chen K; Sun C; Wei J; Wang B
    J Clin Lab Anal; 2023 Nov; 37(21-22):e24981. PubMed ID: 37997497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The core genes of cuproptosis assists in discerning prognostic and immunological traits of clear cell renal cell carcinoma.
    Chu B; Hong Z; Zheng X
    Front Oncol; 2022; 12():925411. PubMed ID: 36212447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
    Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
    Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
    Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
    Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
    Front Genet; 2023; 14():1094793. PubMed ID: 36891150
    [No Abstract]   [Full Text] [Related]  

  • 28. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
    Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
    BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
    Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
    Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
    Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
    Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
    Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
    Front Immunol; 2022; 13():954440. PubMed ID: 36059510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
    Zhang X; Zhou Y; Hu J; Yu X; Xu H; Ba Z; Zhang H; Sun Y; Wang R; Du X; Mou R; Li X; Zhu J; Xie R
    BMC Cancer; 2023 Jun; 23(1):560. PubMed ID: 37330494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 38. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
    Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
    Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative analysis of single-cell and bulk RNA seq to reveal the prognostic model and tumor microenvironment remodeling mechanisms of cuproptosis-related genes in colorectal cancer.
    Chu B; Wang Y; Yang J; Dong B
    Aging (Albany NY); 2023 Dec; 15(23):14422-14444. PubMed ID: 38078879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.